Get the Stockscreener App
1.21
4.72%
-0.06
Ocugen Inc stock is traded at $1.21, with a volume of 4.11M.
It is down -4.72% in the last 24 hours and down -12.95% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.27
Open:
$1.27
24h Volume:
4.11M
Relative Volume:
0.55
Market Cap:
$409.61M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-5.22
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
-11.03%
1M Performance:
-12.95%
6M Performance:
-27.11%
1Y Performance:
+8.04%
1-Day Range:
$1.21
$1.275
1-Week Range:
$1.21
$1.385
52-Week Range:
$0.931
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.21 | 409.61M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
Ocugen Inc (OCGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
OCGN|Ocugen Inc|Price:1.210|Chg%:-0.060 - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocugen Inc (OCGN) Institutional Confidence - TradingKey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches - Traders Union
OCGN Q2'26 Earnings: revenue estimate is 976.14K USD - TradingView
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
OCGN stock holds attention as Ocugen updates its pipeline - AD HOC NEWS
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen (OCGN) targets 250M-share authorization increase tied to $130M converts - Stock Titan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen (OCGN) Proxy filing Summary - Quartr
Ocugen Targets $259 Million in MENA Licensing Deal for OCU400 - MyChesCo
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen licenses gene therapy to Roots Pharmaceutica - BioXconomy
symbol__ Stock Quote Price and Forecast - CNN
Why Is Ocugen (NASDAQ:OCGN) Back on the Penny Stock Radar? - Kalkine Media
Ocugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosa - Minichart
Ocugen signs OCU400 MENA license agreement - grafa.com
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - ir.ocugen.com
Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg - GuruFocus
Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region - Moomoo
Ocugen (NASDAQ: OCGN) lines up OCU400 MENA license with $4M fees and 22% royalty - Stock Titan
Ocugen signs term sheet for OCU400 gene therapy in MENA region By Investing.com - Investing.com South Africa
Ocugen signs term sheet for OCU400 gene therapy in MENA region - Investing.com Nigeria
Ocugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceutical - Quiver Quantitative
Gene therapy for inherited blindness set for MENA launch under Ocugen–Roots pact - Stock Titan
Ocugen inks OCU400 licensing deal for MENA - TipRanks
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances - Yahoo Finance
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances By Investing.com - Investing.com Canada
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances - Investing.com
Ocugen’s Triple-Threat Pipeline: A $130M Cash Injection and a Summer of Make-or-Break Data - ad-hoc-news.de
Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear. - Ad-hoc-news.de
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Participate in Upcoming July Industry Conferences - The Manila Times
Ocugen’s July retina conference talks include OCU410 phase 2 results - Stock Titan
Ocugen, Inc. pursues gene therapy innovation to address rare vision loss conditions - Traders Union
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index - marketscreener.com
OCGN Stock Grinds Higher As Traders Track Tight Range - StocksToTrade
Ocugen’s CFO Makes a Rare Open-Market Buy as Institutional Investors Pile In Ahead of Key Gene The - AD HOC NEWS
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):